News
Releases

AUSTIN, Texas --(BUSINESS WIRE)--Aug. 7, 2026-- Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced that the Compensation Committee of Faeth’s Board of Directors granted two new employees options to purchase an aggregate of 11,000 shares of the Company’s common stock in connection with their

— The data will be presented at the 2026 Summit for Novel Therapeutics in Oncology and Precision Medicine in Cancer conference on August 8 — These data collectively informed PIKTOR dose selection in the ongoing Phase 2 trial in second-line advanced endometrial cancer (Study FTH-PIK-201) AUSTIN,

— Topline results from the Phase 2 PIK-201 trial in endometrial cancer on track for year-end — First patient dosed in the Phase 1b/2 PIK-101 trial in HR+ breast cancer — Company changed name to Faeth Therapeutics, Inc. on June 15, 2026; common stock began trading under the ticker symbol “FTH” on

AUSTIN, Texas --(BUSINESS WIRE)--Jul. 23, 2026-- Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced that the Compensation Committee of Faeth’s Board of Directors granted two new employees options to purchase an aggregate of 25,500 shares of the Company’s common stock in connection with their

— Stockholders approved conversion of the Series B preferred stock issued in the February 2026 acquisition of Faeth Therapeutics and concurrent private placement — — Company changed name to Faeth Therapeutics, Inc. on June 15, 2026; common stock expected to begin trading under the ticker symbol

BOSTON --(BUSINESS WIRE)--Jun. 4, 2026-- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that, effective on June 1, 2026, the Compensation Committee of Sensei’s Board of Directors granted three new employees options to purchase an aggregate of 19,300 shares of the Company’s common stock

First patient dosed in Phase 1b/2 trial of PIKTOR in HR+/HER2- advanced breast cancer Topline Phase 2 data in patients with advanced endometrial cancer expected in second half 2026 BOSTON --(BUSINESS WIRE)--May 15, 2026-- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today reported financial results

PIKTOR is an investigational all-oral, multi-node inhibitor targeting escape routes in the PI3K/AKT/mTOR pathway that single-node inhibitors leave open BOSTON --(BUSINESS WIRE)--May 5, 2026-- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage biotechnology company, announced today that

BOSTON --(BUSINESS WIRE)--Apr. 9, 2026-- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that Company management will present at the 25th Annual Needham Virtual Healthcare Conference on Thursday, April 16 th, 2026 at 12:45 p.m. ET. The live webcast of the presentation may be accessed